ExpertiseUpdated on 26 June 2025
Preclinical Immuno-Modulatory Drug Development in Oncology
About
Abbmira has amassed significant pre-clinical data demonstrating that its experimental small molecule compounds enhance anticancer activity in relevant mouse models via macrophage re-programming. Compound42 binds to a defined intracellular target in tumor associated macrophages (TAMs), which activates these native immune cells to generate an anti-tumor microenvironment.
Field
- CHE - Chemistry
- LIF - Life Sciences
- POSTDOCTORAL FELLOWSHIPS: Hosting Postdoctoral Candidates / Secondments / Placements
- DOCTORAL NETWORKS: Hosting Doctoral Candidates / Secondments / Trainings
Organisation
Similar opportunities
Project cooperation
Preclinical Immuno-modulatory Drug Development in Oncology
- Proposal Idea
- MSCA-DOCTORAL NETWORKS
- Proposal under Development
- MSCA-POSTDOCTORAL FELLOWSHIPS
- POSTDOCTORAL FELLOWSHIP: Looking for an Institution for Secondment
- DOCTORAL NETWORK: Looking for Partner/s (Beneficiaries or Associated Partners)
Marc Creus
CEO at abbmira therapeutics AG
Basel, Switzerland
Expertise
- LIF - Life Sciences
- DOCTORAL NETWORKS: Hosting Doctoral Candidates / Secondments / Trainings
- POSTDOCTORAL FELLOWSHIPS: Hosting Postdoctoral Candidates / Secondments / Placements
Dorthe Helena Larsen
Group Leader at Danish Cancer Institute
Copenhagen, Denmark
Expertise
- PHY - Physics
- LIF - Life Sciences
- ENG - Information Science and Engineering
- DOCTORAL NETWORKS: Hosting Doctoral Candidates / Secondments / Trainings
- POSTDOCTORAL FELLOWSHIPS: Hosting Postdoctoral Candidates / Secondments / Placements
Antonio Napolitano
Medical Physicist at Bambino Gesù Children's Hospital
Rome, Italy